Clinical trial
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
NCT01436968
Study timeline
Study start (unknown)2011-09-01Date precision: month
Registry last updated2026-10-02
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
Aglatimagene besadenovec + valacyclovirBIOLOGICAL
Placebo + valacyclovirBIOLOGICAL
Sponsors & collaborators
Candel Therapeutics, Inc.lead sponsor
Mapped research locations
HoustonTexas, United States3BaltimoreMaryland, United States3AustinTexas, United States3ChicagoIllinois, United States2DallasTexas, United States2San AntonioTexas, United States2TampaFlorida, United States2AlbuquerqueNew Mexico, United States2ScottsdaleArizona, United States2PhiladelphiaPennsylvania, United States1CincinnatiOhio, United States1PortlandOregon, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01436968 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.